Key clinical point: The all-oral combination of selinexor, lenalidomide, and dexamethasone has demonstrated efficacy in patients with relapsed/refractory multiple myeloma, particularly those who are lenalidomide-naive.
Major finding: The combination produced an overall response rate of 60% in all evaluable patients and 92% in lenalidomide-naive patients.
Study details: One arm of a phase 1/2 study. The arm enrolled 24 patients who had received at least one prior line of therapy.
Disclosures: The trial is sponsored by Karyopharm Therapeutics. Dr. White disclosed relationships with Karyopharm, Amgen, Celgene, Janssen, Sanofi, and Takeda.
White D et al. IMW 2019, Abstract OAB-083.